BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 20712900)

  • 21. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.
    Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P
    J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast.
    Reis-Filho JS; Milanezi F; Amendoeira I; Albergaria A; Schmitt FC
    J Clin Pathol; 2002 Dec; 55(12):936-9. PubMed ID: 12461063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family.
    Abdel-Fatah TM; Powe DG; Hodi Z; Reis-Filho JS; Lee AH; Ellis IO
    Am J Surg Pathol; 2008 Apr; 32(4):513-23. PubMed ID: 18223478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A study of the role of Notch1 and JAG1 gene methylation in development of breast cancer.
    Sun H; Li K; Shen S
    Med Oncol; 2016 Apr; 33(4):35. PubMed ID: 26971121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of the ultrasound imaging of breast cancer and the expression of molecular biological indexes.
    Xu J; Li F; Chang F
    Pak J Pharm Sci; 2017 Jul; 30(4(Suppl.)):1425-1430. PubMed ID: 29043992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Notch1 single nucleotide polymorphism rs3124591 is associated with the risk of development of invasive ductal breast carcinoma in a Chinese population.
    Cao YW; Wan GX; Zhao CX; Hu JM; Li L; Liang WH; Li WQ; Li YC; Li YX; Du XM; Yu SY; Li F
    Int J Clin Exp Pathol; 2014; 7(7):4286-94. PubMed ID: 25120811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.
    Liu C; Zhang H; Shuang C; Lu Y; Jin F; Xu H; Lu P
    Med Oncol; 2010 Sep; 27(3):747-52. PubMed ID: 19657752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased expression of centrosomal alpha, gamma-tubulin in atypical ductal hyperplasia and carcinoma of the breast.
    Niu Y; Liu T; Tse GM; Sun B; Niu R; Li HM; Wang H; Yang Y; Ye X; Wang Y; Yu Q; Zhang F
    Cancer Sci; 2009 Apr; 100(4):580-7. PubMed ID: 19215229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.
    Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B
    Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.
    Wong H; Lau S; Leung R; Chiu J; Cheung P; Wong TT; Liang R; Epstein RJ; Yau T
    Med Oncol; 2012 Sep; 29(3):1536-42. PubMed ID: 21983862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical analysis of Metadherin in proliferative and cancerous breast tissue.
    Su P; Zhang Q; Yang Q
    Diagn Pathol; 2010 Jun; 5():38. PubMed ID: 20565850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mean nuclear area and metallothionein expression in ductal breast tumors: correlation with estrogen receptor status.
    El Sharkawy SL; Farrag AR
    Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):108-12. PubMed ID: 18227734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical study of matrix metalloproteinase 9 and tissue inhibitor of matrix metalloproteinase 1 in benign and malignant breast tissue--strong expression in intraductal carcinomas of the breast.
    Rahko E; Kauppila S; Pääkkö P; Blanco G; Apaja-Sarkkinen M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Jukkola A
    Tumour Biol; 2009; 30(5-6):257-64. PubMed ID: 19887890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies.
    Renshaw AA; Gould EW
    Pathology; 2016 Jan; 48(1):25-9. PubMed ID: 27020205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
    Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
    J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Utility of SOX10 Immunohistochemical Staining in Breast Pathology.
    Rammal R; Goel K; Elishaev E; Rinda Soong T; Jones MW; Zhao C; Clark BZ; Carter GJ; Yu J; Fine JL; Villatoro TM; Harinath L; Bhargava R
    Am J Clin Pathol; 2022 Nov; 158(5):616-625. PubMed ID: 36000970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. P63 and cytokeratin8/18 expression in breast, atypical ductal hyperplasia, ductal carcinoma in situ and invasive duct carcinoma.
    Shamloula MM; El-Shorbagy SH; Saied EM
    J Egypt Natl Canc Inst; 2007 Sep; 19(3):202-10. PubMed ID: 19190693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.